- Overview
- Bayer Group
- Stock
- Debt
- Reports
- Annual Stockholders’ Meeting 2020
- Events
- Inside Information
- Latest Inside Information
- Archive Overview
- Inside Information 2019
- Inside Information 2018
- Inside Information 2017
- Ad-hoc 2016
- Ad-hoc 2015
- Ad-hoc 2014
- Ad-hoc 2013
- Ad-hoc 2012
- Ad-hoc 2011
- Ad-hoc 2010
- Ad-hoc 2009
- Ad-hoc 2008
- Ad-hoc 2007
- Ad-hoc 2006
- Ad-hoc 2005
- Ad-hoc 2004
- Ad-hoc 2003
- Ad-hoc 2002
- Ad-hoc 2001
- Ad-hoc 2000
- Ad-hoc 1999
- Ad-hoc 1998
- News
- Investor News
- Press
- Archive
- Overview
- Investor News 2019
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Handouts
- Downloads
- Service
Bayer HealthCare Investor Day 2007
Tuesday, June 19, 2007
Start at approx 8.30 a.m. CEST (6:30 a.m. GMT)
Location: BayKomm, Leverkusen, Germany
Bayer HealthCare Investor Day 2007:
Bayer raises guidance for 2007 and 2009
Underlying EBITDA margin of the Bayer Group to exceed 22 percent by 2009 / Improved earnings forecast for Bayer HealthCare / Integration of Bayer Schering Pharma proceeding more quickly than planned / New research strategy adopted and pharmaceutical pipeline optimized / Current clinical studies confirm the potential of rivaroxaban / Nexavar® submitted in HCC / New drug to control bleeding during surgery inlicensed more
MP3 audio recording (presentations and discussion)
Presentation by Werner Wenning and Arthur Higgins
Presentation by Prof. Dr. Andreas Busch
Presentation by Dr. Kemal Malik
Presentation by Dr. Gunnar Riemann
Presentation by Dr. Ulrich Köstlin
Presentation by Sandra Peterson
Presentation by Lykele van der Broek
| Agenda | Download PDF collect (65 KB) |
| Presentations | |
|---|---|
| Werner Wenning, CEO of Bayer AG, und Arthur Higgins, CEO of Bayer HealthCare: "Building on Our Success" | Download PDF collect (404 KB) |
| Prof. Dr. Andreas Busch, Head of Global Drug Discovery, Member of the Board of Bayer Schering Pharma: "Addressing High Medical Needs, Building a Sustainable Pipeline to Ensure Future Growth (1)" | Download PDF collect (521 KB) |
| Dr. Kemal Malik, Head of Global Development, Member of the Board of Bayer Schering Pharma: "Addressing High Medical Needs, Building a Sustainable Pipeline to Ensure Future Growth (2)" | Download PDF collect (321 KB) |
| Dr. Gunnar Riemann, Business Units Oncology, Specialized Therapeutics, Cardiology/Hematology, Member of the Board of Bayer Schering Pharma: "Growth Through Our Portfolio of Marketed Products (1)" | Download PDF collect (880 KB) |
| Dr. Ulrich Köstlin, Business Units Women‘s HealthCare, Diagnostic Imaging, Primary Care, Member of the Board of Bayer Schering Pharma: "Growth Through Our Portfolio of Marketed Products (2)" | Download PDF collect (365 KB) |
| Gary Balkema, President, Consumer Care: "Bayer Consumer Care: Well Positioned for Future Success in Attractive Markets" | Download PDF collect (303 KB) |
| Sandra Peterson, President, Diabetes Care: "Successful Turnaround of the Diabetes Care Business Achieved - Committed to Continued Outperformance" | Download PDF collect (499 KB) |
| Lykele van der Broek, President, Animal Health: "Bayer Animal Health – A Top Player in an Attractive Market" | Download PDF collect (291 KB) |
| Arthur Higgins, CEO of Bayer HealthCare: "Concluding Remarks" | Download PDF collect (103 KB) |